Thus, MCT 1 was proposed to be a potential biomarker for 3BP sensitivity and opens the possibility that the selectivity of cancer-expressed transporters can be exploited for the delivery of toxic molecules to tumours. This evidence concerns the gene SLC16A1 and neoplasm.